Furet P - Search Results

1

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.

Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, Kauffmann A, Guthy D, Erdmann D, De Pover A, Furet P, Gao H, Ferretti S, Wang Y, Trappe J, Brachmann SM, Maira SM, Wilson C, Boehm M, Garcia-Echeverria C, Chene P, Wiesmann M, Cozens R, Lehar J, Schlegel R, Caravatti G, Hofmann F, Sellers WR. Fritsch C, et al. Among authors: furet p. Mol Cancer Ther. 2014 May;13(5):1117-29. doi: 10.1158/1535-7163.MCT-13-0865. Epub 2014 Mar 7. Mol Cancer Ther. 2014. PMID: 24608574

2

4-Amidinoindan-1-one 2'-amidinohydrazone: a new potent and selective inhibitor of S-Adenosylmethionine decarboxylase.

Stanek J, Caravatti G, Frei J, Furet P, Mett H, Schneider P, Regenass U. Stanek J, et al. Among authors: furet p. J Med Chem. 1993 Jul 23;36(15):2168-71. doi: 10.1021/jm00067a014. J Med Chem. 1993. PMID: 8340919

3

S-adenosylmethionine decarboxylase inhibitors: new aryl and heteroaryl analogues of methylglyoxal bis(guanylhydrazone).

Stanek J, Caravatti G, Capraro HG, Furet P, Mett H, Schneider P, Regenass U. Stanek J, et al. Among authors: furet p. J Med Chem. 1993 Jan 8;36(1):46-54. doi: 10.1021/jm00053a007. J Med Chem. 1993. PMID: 8421290

4

Dual specificity of Src homology 2 domains for phosphotyrosine peptide ligands.

Gay B, Furet P, García-Echeverría C, Rahuel J, Chène P, Fretz H, Schoepfer J, Caravatti G. Gay B, et al. Among authors: furet p. Biochemistry. 1997 May 13;36(19):5712-8. doi: 10.1021/bi962642y. Biochemistry. 1997. PMID: 9153411

5

Discovery of 3-aminobenzyloxycarbonyl as an N-terminal group conferring high affinity to the minimal phosphopeptide sequence recognized by the Grb2-SH2 domain.

Furet P, Gay B, García-Echeverría C, Rahuel J, Fretz H, Schoepfer J, Caravatti G. Furet P, et al. J Med Chem. 1997 Oct 24;40(22):3551-6. doi: 10.1021/jm9702185. J Med Chem. 1997. PMID: 9357522

6

Potent antagonists of the SH2 domain of Grb2: optimization of the X+1 position of 3-amino-Z-Tyr(PO3H2)-X+1-Asn-NH2.

García-Echeverría C, Furet P, Gay B, Fretz H, Rahuel J, Schoepfer J, Caravatti G. García-Echeverría C, et al. Among authors: furet p. J Med Chem. 1998 May 21;41(11):1741-4. doi: 10.1021/jm970856n. J Med Chem. 1998. PMID: 9599224 No abstract available.

7

Structural basis for the high affinity of amino-aromatic SH2 phosphopeptide ligands.

Rahuel J, García-Echeverría C, Furet P, Strauss A, Caravatti G, Fretz H, Schoepfer J, Gay B. Rahuel J, et al. Among authors: furet p. J Mol Biol. 1998 Jun 19;279(4):1013-22. doi: 10.1006/jmbi.1998.1790. J Mol Biol. 1998. PMID: 9642078

8

Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain.

Furet P, Gay B, Caravatti G, García-Echeverría C, Rahuel J, Schoepfer J, Fretz H. Furet P, et al. J Med Chem. 1998 Aug 27;41(18):3442-9. doi: 10.1021/jm980159a. J Med Chem. 1998. PMID: 9719597

9

Structure-based design of peptidomimetic ligands of the Grb2-SH2 domain.

Schoepfer J, Gay B, Caravatti G, Garcia-Echeverria C, Fretz H, Rahuel J, Furet P. Schoepfer J, et al. Among authors: furet p. Bioorg Med Chem Lett. 1998 Oct 20;8(20):2865-70. doi: 10.1016/s0960-894x(98)00513-7. Bioorg Med Chem Lett. 1998. PMID: 9873638

10

Highly potent inhibitors of the Grb2-SH2 domain.

Schoepfer J, Fretz H, Gay B, Furet P, García-Echeverría C, End N, Caravatti G. Schoepfer J, et al. Among authors: furet p. Bioorg Med Chem Lett. 1999 Jan 18;9(2):221-6. doi: 10.1016/s0960-894x(98)00701-x. Bioorg Med Chem Lett. 1999. PMID: 10021933

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

143 results

Search Page

Filters